Abstract Library

#4480 Efficacy of regional and systemic therapies for refractory hypoglycaemia in malignant insulinoma

Introduction: Insulinoma is a rare neuroendocrine tumour characterised by inappropriate autonomous insulin secretion.

Conference:

Presenting Author: Koch R

Authors: Koch R, McGarrah P, Eiring R, Hobday T, Halfdanarson T,

Keywords: Insulinoma, radioligand therapy,

#3335 Efficacy of somatostatin analogue (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs)

Introduction: Currently, there is minimal published data on the efficacy of SSAs for well-differentiated G3 NETs. Randomized trials have demonstrated a progression-free survival (PFS) benefit and limited response for lower grade 1-2 NETs, but the optimal therapy for metastatic G3 NETs is unknown.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: McGarrah P

Authors: McGarrah P, Liu A, Hobday T, Starr J, Kendi A,

Keywords: somatostatin analogues, lanreotide, octreotide, well-differentiated grade 3 neuroendocrine tumor, G3net, G3nen,

#3334 Utility of midpoint imaging in patients receiving peptide receptor radionuclide therapy (PRRT) for advanced progressive midgut neuroendocrine tumors (NET)

Introduction: The NETTER-1 trial formed the basis for standard practice of PRRT, consisting of 4 cycles with follow-up imaging during midtreatment and after completion to evaluate disease response. However, in clinical practice the timing of midpoint imaging varies if performed at all, and it is unclear how often it influences subsequent management.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Norman A, Wee C, Hobday T, Kendi A, Johnson G,

Keywords: midpoint imaging, PRRT, clinical decision making,

#3173 Intestinal obstruction (IO) in patients receiving peptide receptor radionuclide therapy (PRRT) for gastro-enteropancreatic neuroendocrine tumors (GEP-NETs): Potential predictors and association with overall survival (OS)

Introduction: There are concerns for the risk of IO in patients with GEPNETs, especially in cases with peritoneal metastases or mesenteric vascular encasement.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Badawy M

Authors: Badawy M, Hobday T, Johnson G, Halfdanarson T, Young J,

Keywords: gastrointestinal NETs, PRRT (Lu-DOTATATE), intestinal obstruction, overall survival,

#3172 Peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE following liver directed therapy (LDT) in neuroendocrine tumors (NETs): Hepatotoxicity and impact on progression-free survival (PFS)

Introduction: PRRT (Lu-DOTATATE) and LDT (e.g. hepatic artery embolization) are commonly used in treating liver dominant NETs. Hepatotoxicity from PRRT in the setting of metastatic disease and prior liver-directed therapy is an important consideration. There is a concern for hepatotoxicity in patients receiving PRRT based on the literature, but there is limited data on patients who may have had a prior liver injury from LDT.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Badawy M

Authors: Badawy M, Halfdanarson T, Johnson G, Hobday T, Young J,

Keywords: hepatotoxicity, PRRT (LU-DOTATATE), liver targeted therapy, progression-free survival, NEN, NET,